Where is smartbax located?

smartbax is headquartered in Munich, Germany.

Which legal entities is smartbax associated with?

smartbax is associated with smartbax GmbH and 1 other.

How many employees does smartbax have?

As of Sep 30, 2026, the latest employee count at smartbax is 8.

Is smartbax a funded company?

smartbax is a funded company, having raised a total of $7.51M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of smartbax?

smartbax's latest funding was a $***** Seed round on Jun 30, 2026, with participation from 5 investors. Its primary sector is Infectious Diseases. In Germany, the Infectious Diseases sector has seen $22.7M in funding in 2026 to date.

Where does smartbax rank among its competitors?

smartbax ranks 5th amongst 221 active competitors, of which 78 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was smartbax, which secured $7.19M in Jun, 2026.

Who are the top competitors of smartbax?

smartbax's top competitors include Spero Therapeutics, LimmaTech Biologics and Bioversys. Among them, smartbax secured the most recent funding round in June, 2026.

smartbax - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of multi-targeted antibacterial compounds. The company creates multi-targeted antibacterial compounds that are effective against multi-drug resistance infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Website: www.smartbax.de/
Email ID: *****@smartbax.de
Phone Number: +49 **********

Key Metrics

Founded Year

2021

Location

Munich, Germany

Stage

Seed

Total Funding

$7.51M in 4 rounds

Latest Funding Round

Seed, Jun 30, 2026, $*****

Investors

Bayern Kapital & 5 more

Ranked

5^th among 221 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

Spero Therapeutics & 273 more

View smartbax's full profile

smartbax is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
smartbax GmbH CIN: D2601_HRB265575 , Germany, Active	Apr 27, 2021	-	-
smartbax GmbH CIN: HRB265575 , Germany, Active	Apr 26, 2021	-	-

smartbax has raised a total funding of $7.51M over 4 rounds. Its latest funding round was a Seed round on Jun 30, 2026 for $*****. 5 investors participated in its latest round. smartbax has 5 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of smartbax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2026	3505761	Seed	8465840	7732951	3467801	2471236
Oct 22, 2025	4499520	Seed	3815478	4512226	8047260	UnternehmerTUM & 2 more
May 23, 2023	9299423	Seed	7904009	3379705	3998933	Boehringer Ingelheim Venture Fund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of smartbax's funding rounds and investors

The founders of smartbax are Marco Janezic and Stephan Sieber.

Here are the details of smartbax's key team members:

Marco Janezic: Co-Founder of smartbax and founder of 1 other company. They are also an angel investor in 2 startups.
Stephan Sieber: Co-Founder of smartbax.

View details of smartbax's Founder profiles and Board Members

smartbax's employee count trend

smartbax has 8 employees as of Sep 26. Here is smartbax's employee count trend over the years:

Uncover smartbax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of smartbax include Spero Therapeutics, LimmaTech Biologics and Bioversys. Here is the list of Top 10 competitors of smartbax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	67/100
2nd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	65/100
3rd	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
4th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	60/100
5th	smartbax 2021, Munich (Germany), Seed	Developer of multi-targeted antibacterial compounds	$7.51M	Boehringer Ingelheim Venture Fund, Bayern Kapital ... & 4 others	60/100
6th	Pattern Bioscience 2016, Austin (United States), Series C	Provider of multiple diagnostics platforms for infectious diseases	$105M	Illumina Ventures, CARB-X & 3 others	59/100
7th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Hillhouse & 12 others	58/100
8th	Clarametyx 2019, Columbus (United States), Series A	Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections	$33M	Ohio Innovation Fund, C Bio Investors & 8 others	58/100
9th	Omnix Medical 2015, Jerusalem (Israel), Series C	Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections	$25M	Harel Group, Europa & 12 others	57/100
10th	ContraFect 2008, Yonkers (United States), Public	Developer of therapeutics for the treatment of antibiotic-resistant infections	$38.7M	Maxim Group, Collage Venture Partners & 5 others	57/100